CELLTRION PHARM, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 89,900 KRW | -0.88% |
|
+0.22% | -2.49% |
| 01-16 | Celltrion Holdings Actively Pursuing Nasdaq Listing | MT |
| 01-02 | Celltrion's Shares Climb After Merger With Affiliate | DJ |
| Sales 2019 | 174B 126M 172M | Sales 2020 | 234B 170M 232M | Capitalization | 8,705B 6.33B 8.64B |
|---|---|---|---|---|---|
| Net income 2019 | 8.6B 6.25M 8.54M | Net income 2020 | 20.94B 15.22M 20.79M | EV / Sales 2019 | 9.06 x |
| Net Debt 2019 | 149B 108M 148M | Net Debt 2020 | 163B 119M 162M | EV / Sales 2020 | 38 x |
| P/E ratio 2019 |
166
x | P/E ratio 2020 |
417
x | Employees | 328 |
| Yield 2019 * |
-
| Yield 2020 |
-
| Free-Float | 47.03% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.88% | ||
| 1 week | +0.22% | ||
| Current month | -14.46% | ||
| 1 month | -20.23% | ||
| 3 months | -14.38% | ||
| 6 months | +46.80% | ||
| Current year | -2.49% |
1 week
89 900.00
92 700.00
1 month
87 700.00106 800.00
Current year
87 700.00133 300.00
1 year
57 714.29133 300.00
3 years
53 523.81158 245.82
5 years
23 556.96236 729.00
10 years
5 962.91236 729.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jeong-Soo Suh
CEO | Chief Executive Officer | 64 | 16-03-27 |
Yu-Jin Jeon
DFI | Director of Finance/CFO | 51 | - |
Jung-Jin Seo
CHM | Chairman | 66 | 09-01-22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jung-Jin Seo
CHM | Chairman | 66 | 09-01-22 |
Jeong-Soo Suh
CEO | Chief Executive Officer | 64 | 16-03-27 |
Haeng-Ok Kim
BRD | Director/Board Member | 72 | 14-03-27 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.75% | 2 M€ | -14.14% | ||
| 0.03% | 15 M€ | +11.24% | ||
| 0.01% | 2,808 M€ | +5.90% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 89,900 | -0.88% | 83,276 |
| 24-04-25 | 90,700 | -1.31% | 54,177 |
| 24-04-24 | 91,900 | +0.66% | 76,848 |
| 24-04-23 | 91,300 | -0.33% | 69,731 |
| 24-04-22 | 91,600 | +2.12% | 102,415 |
End-of-day quote Korea S.E., April 25, 2024
More quotes
Celltrion Pharm Inc is a Korea-based company engaged in the manufacture and sale of pharmaceuticals. The Companyâs products include hepatotonics, analgesics, antipyretics, anti-inflammatory drugs, antihistamines, respiratory apparatus drugs, circularly system drugs, digestives and stomachic drugs, hormone disease drugs, antibiotics, nutrients, tonics, and other drugs. It also provides ethical drugs and over-the-counter (OTC) drugs. The Company distributes its products in domestic market and overseas markets such as Philippines, Kazakhstan, Cambodia and other Southeast Asia countries.
Sector
Pharmaceuticals
Calendar
2024-05-09
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -2.49% | 2.7B | |
| +19.62% | 43.34B | |
| +20.44% | 21.96B | |
| +10.86% | 14.09B | |
| +13.07% | 13.64B | |
| +37.46% | 11.43B | |
| -8.59% | 6.86B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.22B |
- Stock Market
- Equities
- A068760 Stock
